R&D Trends

Merck, BGI collaborate

Tuesday, September 13, 2011 01:05 PM

Merck and BGI have established a collaboration to focus on the discovery and development of biomarkers and genomic technologies. Under the agreement scientists from Merck and BGI will work closely together to identify and characterize biomarkers with an emphasis on drug discovery, drug development and diagnostics applications across a wide range of therapeutic areas.

More... »

Evotec partners with Roche in $820 million Alzheimer’s deal

Tuesday, September 6, 2011 01:10 PM

Evotec has signed a new agreement with partner Roche to develop a compound with potential in Alzheimer's disease, replacing an antidepressant program which was dropped in May, according to PharmaTimes.

More... »

Skyline, Clavis collaborate in Leukemia research

Tuesday, September 6, 2011 12:19 PM

The Dutch biotech company Skyline Diagnostics and the Norwegian drug development company Clavis Pharma have signed a research agreement. Under this agreement, Skyline will investigate gene expression biomarkers for selection of individual Acute Myeloid Leukemia (AML) patients that may benefit from a new AML drug in development at Clavis. This drug, elacytarabine, is a novel elaidic acid derivative of cytarabine and currently undergoing the CLAVELA phase III study for treatment of patients with relapsed/refractory AML.

More... »

Report: Biomarkers market expected to reach $34 billion

Thursday, September 1, 2011 02:19 PM

Clinical development should emerge as the fastest-growing segment of a global biomarkers market expected to reach $34 billion by 2017, a new report predicts, according to PharmaTimes.

More... »

OrbiMed launches $600 million royalty fund

Thursday, September 1, 2011 10:53 AM

OrbiMed, an investment management firm focused on the healthcare sector, has reported the final closing of a new fund that acquires healthcare royalty streams and provides structured debt capital to healthcare companies. The fund, the "Royalty Opportunities S.ar.l.,” is domiciled in Luxembourg and will invest worldwide to take advantage of OrbiMed's global platform. Investors in the $600 million fund include some of the largest endowments, foundations and financial institutions globally.

More... »

Biogen, Novo Nordisk collaborate with Adimab

Tuesday, August 30, 2011 02:36 PM

Adimab has initiated two independent collaborations with Biogen Idec and Novo Nordisk.

More... »

Lundbeck Canada donates $2.7 million towards depression study

Tuesday, August 30, 2011 10:25 AM

The Canadian subsidiary of neurological disease specialist Lundbeck has donated $2.7 million towards a nationwide study aimed at identifying biomarkers of major depression and bipolar disorder, according to PharmaTimes.

More... »

Boehringer builds $42.5 million R&D facility

Thursday, August 25, 2011 10:57 AM

Boehringer Ingelheim Pharmaceuticals, broke ground on a new $42.5-million safety assessment building to be built over the next two years on its 294-acre campus in Ridgefield and Danbury, according to the Ridgefield Press.

More... »

Bio-Images, CPS Research collaborate

Thursday, August 25, 2011 10:12 AM

A strategic partnership between two research organizations based in Glasgow, Scotland will combine formulation expertise with clinical trial capabilities to streamline the development and passage to market of new, enhanced drug formats, according to PharmaTimes.

More... »

American Cancer Society enrolls thousands in prevention study

Wednesday, August 24, 2011 11:33 AM

For the past two years, the American Cancer Society has been enrolling people across the country in its latest research project, cancer prevention study-3, according to a report in the Indianapolis Star. In the first week of October, eight of Indianapolis’ major employers will contribute, signing up people at their work sites.

More... »